Overview
Lord’s Mark Industries Limited announced that its AI‑powered dialysis ecosystem, branded as Renalyx, has obtained registration from the United Kingdom’s Medicines & Healthcare products Regulatory Agency (MHRA) in London. The company describes the achievement as the world’s first AI‑driven dialysis platform to secure such regulatory clearance and the first Indian firm to do so under the India‑UK Free Trade Agreement.
Regulatory Details
The MHRA registration lists Renalyx Health Systems Pvt. Ltd. as the manufacturer and covers the haemodialysis system intended for both institutional and home use. The device is classified under Global Medical Device Nomenclature (GMDN) Code 58131. The MHRA communication explicitly states that the registration does not constitute accreditation, certification, or approval by the UK Competent Authority, but it provides a formal recognition of the manufacturer and device.
Product and Ecosystem Description
Renalyx combines a smart haemodialysis machine with an AI‑driven clinical intelligence platform called RenalOS, alongside an integrated operational model that extends care beyond the dialysis session. The ecosystem delivers real‑time monitoring of treatment parameters, predictive alerts, data‑driven decision support during sessions, and remote patient monitoring after discharge. This connected, intelligence‑led approach is positioned as a shift from a machine‑centric to an intelligence‑driven renal‑care model.
International Expansion Plan
With the MHRA registration in place, Lord’s Mark plans to commence exports of the Renalyx system to the United Kingdom and other UK‑allied markets starting in early January 2027. The company’s international business model envisages a dual pathway: supplying the machines to healthcare providers and potentially establishing and operating its own dialysis centres in those markets. This strategy would allow participation across the renal‑care value chain, encompassing technology provision, AI‑enabled clinical services, infrastructure management, and direct patient care.
Leadership Commentary
Dr. Sachidanand Upadhyay, Managing Director & CEO of Lord’s Mark Industries Limited, stated that the registration validates the broader vision of building Indian‑origin medical technology for global markets. He emphasized that the milestone is not merely a regulatory win but a step toward delivering a connected, intelligent, and scalable renal‑care solution worldwide, with the UK serving as a key entry point.
Significance for the Indian Med‑Tech Sector
The announcement underscores the growing capability of Indian med‑tech firms to develop AI‑enabled, connected healthcare solutions that meet international regulatory standards. It also highlights the potential for Indian companies to leverage trade agreements, such as the India‑UK FTA, to accelerate market entry.
Disclaimer
The press release is provided under an arrangement with NRDPL; PTI does not assume editorial responsibility.